BioSpace News Archive

Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belgium, and supports Flemish companies.

Ocelot Bio , Inc. today announced the close of a $36 million Series A financing led by RA Capital Management, Venrock and Vivo Capital and the appointment of Katherine Vega Stultz, an experienced pharmaceutical and biotech executive, as president and chief executive officer.

Aditxt, Inc., a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

MedX Health Corp., a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed as the Company’s President and Chief Executive Officer, effective immediately.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported its financial results for the full year 2021 and provided a corporate update.

Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 Annual Results.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), today announced that CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2 (CLDN18.2), has completed the first patient enrollment in the confirmatory Phase II clinical trial in Beijing Cancer Hospital in China.

PacBio, a leading developer of high-quality, highly accurate, sequencing platforms, announced the company’s expansion to better serve customers in the Europe, Middle East and Africa region.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-BasedTherapies in the Era of Precision Medicine.